scholarly journals The VICTORY (Investigation of Inflammacheck to Measure Exhaled Breath Condensate Hydrogen Peroxide in Respiratory Conditions) Study: Protocol for a Cross-sectional Observational Study (Preprint)

2020 ◽  
Author(s):  
Lauren Fox ◽  
Jessica Gates ◽  
Ruth De Vos ◽  
Laura Wiffen ◽  
Alexander Hicks ◽  
...  
Keyword(s):  
Health Care ◽  
Hydrogen Peroxide ◽  
Observational Study ◽  
Lung Disease ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Cross Sectional ◽  
Handheld Device ◽  
Respiratory Conditions ◽  
Breath Condensate

BACKGROUND More than 7% of the world’s population is living with a chronic respiratory condition. In the United Kingdom, lung disease affects approximately 1 in 5 people, resulting in over 700,000 hospital admissions each year. People with respiratory conditions have several symptoms and can require multiple health care visits and investigations before a diagnosis is made. The tests available can be difficult to perform, especially if a person is symptomatic, leading to poor quality results. A new, easy-to-perform, point-of-care test that can be performed in any health care setting and that can differentiate between various respiratory conditions would have a significant, beneficial impact on the ability to diagnose respiratory diseases. OBJECTIVE The objective of this study is to use a new handheld device (Inflammacheck) in different respiratory conditions to measure the exhaled breath condensate hydrogen peroxide (EBC H<sub>2</sub>O<sub>2</sub>) and compare these results with those of healthy controls and with each other. This study also aims to determine whether the device can measure other parameters, including breath humidity, breath temperature, breath flow dynamics, and end tidal carbon dioxide. METHODS We will perform a single-visit, cross-sectional observational study of EBC H<sub>2</sub>O<sub>2</sub> levels, as measured by Inflammacheck, in people with respiratory disease and volunteers with no known lung disease. Participants with a confirmed diagnosis of asthma, chronic obstructive pulmonary disease, lung cancer, bronchiectasis, pneumonia, breathing pattern disorder, and interstitial lung disease as well as volunteers with no history of lung disease will be asked to breathe into the Inflammacheck device to record their breath sample. RESULTS The results from this study will be available in 2022, in anticipation of COVID-19–related delays. CONCLUSIONS This study will investigate the EBC H<sub>2</sub>O<sub>2</sub>, as well as other exhaled breath parameters, for use as a future diagnostic tool.

scholarly journals The VICTORY (Investigation of Inflammacheck to Measure Exhaled Breath Condensate Hydrogen Peroxide in Respiratory Conditions) Study: Protocol for a Cross-sectional Observational Study

10.2196/23831 ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. e23831
Author(s):  
Lauren Fox ◽  
Jessica Gates ◽  
Ruth De Vos ◽  
Laura Wiffen ◽  
Alexander Hicks ◽  
...  
Keyword(s):  
Health Care ◽  
Hydrogen Peroxide ◽  
Observational Study ◽  
Lung Disease ◽  
Exhaled Breath Condensate ◽  
Exhaled Breath ◽  
Cross Sectional ◽  
Handheld Device ◽  
Respiratory Conditions ◽  
Breath Condensate

Background More than 7% of the world’s population is living with a chronic respiratory condition. In the United Kingdom, lung disease affects approximately 1 in 5 people, resulting in over 700,000 hospital admissions each year. People with respiratory conditions have several symptoms and can require multiple health care visits and investigations before a diagnosis is made. The tests available can be difficult to perform, especially if a person is symptomatic, leading to poor quality results. A new, easy-to-perform, point-of-care test that can be performed in any health care setting and that can differentiate between various respiratory conditions would have a significant, beneficial impact on the ability to diagnose respiratory diseases. Objective The objective of this study is to use a new handheld device (Inflammacheck) in different respiratory conditions to measure the exhaled breath condensate hydrogen peroxide (EBC H2O2) and compare these results with those of healthy controls and with each other. This study also aims to determine whether the device can measure other parameters, including breath humidity, breath temperature, breath flow dynamics, and end tidal carbon dioxide. Methods We will perform a single-visit, cross-sectional observational study of EBC H2O2 levels, as measured by Inflammacheck, in people with respiratory disease and volunteers with no known lung disease. Participants with a confirmed diagnosis of asthma, chronic obstructive pulmonary disease, lung cancer, bronchiectasis, pneumonia, breathing pattern disorder, and interstitial lung disease as well as volunteers with no history of lung disease will be asked to breathe into the Inflammacheck device to record their breath sample. Results The results from this study will be available in 2022, in anticipation of COVID-19–related delays. Conclusions This study will investigate the EBC H2O2, as well as other exhaled breath parameters, for use as a future diagnostic tool.

scholarly journals Using the Inflammacheck Device to Measure the Level of Exhaled Breath Condensate Hydrogen Peroxide in Patients With Asthma and Chronic Obstructive Pulmonary Disease (The EXHALE Pilot Study): Protocol for a Cross-Sectional Feasibility Study (Preprint)

2017 ◽  
Author(s):  
Daniel M Neville ◽  
Carole Fogg ◽  
Thomas P Brown ◽  
Thomas L Jones ◽  
Eleanor Lanning ◽  
...  
Keyword(s):  
Hydrogen Peroxide ◽  
Pilot Study ◽  
Airway Inflammation ◽  
Exhaled Breath Condensate ◽  
Symptom Control ◽  
Chronic Obstructive ◽  
Exhaled Breath ◽  
Cross Sectional ◽  
Obstructive Pulmonary Disease ◽  
Breath Condensate

BACKGROUND Asthma and Chronic Obstructive Pulmonary Disease (COPD) are common conditions that affect over 5 million people in the United Kingdom. These groups of patients suffer significantly from breathlessness and recurrent exacerbations that can be difficult to diagnose and go untreated. A common feature of COPD and asthma is airway inflammation that increases before and during exacerbations. Current methods of assessing airway inflammation can be invasive, difficult to perform, and are often inaccurate. In contrast, measurement of exhaled breath condensate (EBC) hydrogen peroxide (H2O2) is performed during normal tidal breathing and is known to reflect the level of global inflammation in the airways. There is a need for novel tools to diagnose asthma and COPD earlier and to detect increased airway inflammation that precedes an exacerbation. OBJECTIVE The aim of this study was to explore the use of a new handheld device (called Inflammacheck) in measuring H2O2 levels in EBC. We will study whether it can measure EBC H2O2 levels consistently and whether it can be used to differentiate asthma and COPD from healthy controls. METHODS We will perform a cross-sectional, feasibility, pilot study of EBC H2O2 levels, as measured by Inflammacheck, and other markers of disease severity and symptom control in patients with asthma and COPD and volunteers with no history of lung disease. Participants will be asked to provide an exhaled breath sample for measurement of their EBC H2O2 using Inflammacheck. The result will be correlated with disease stage, spirometry, fractional exhaled nitric oxide (FeNO), and symptom control scores. RESULTS This study’s recruitment is ongoing; it is anticipated that the results will be available in 2018. CONCLUSIONS The EXhaled Hydrogen peroxide As a marker of Lung diseasE (EXHALE) pilot study will provide an evaluation of a new method of measuring EBC H2O2. It will assess the device’s consistency and ability to distinguish airway inflammation in asthma and COPD compared with healthy controls.

Sign in / Sign up

Export Citation Format

Share Document